Recently, Siderowf and colleagues reported the analysis of CSF samples from 1123 participants, including patients diagnosed with sporadic PD, genetic forms of PD linked to LRKK2 and GDA mutations (including normal carriers), subjects with RBD and controls. This evidence concerns the gene GDA and Parkinson disease.